Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Peter McCroskery"'
Autor:
Paolo Strati, Lori Ann Leslie, Parveen Shiraz, L Elizabeth Budde, Olalekan O. Oluwole, Matthew Ulrickson, Aravind Ramakrishnan, Jennifer Sun, Rhine Shen, Justyna Kanska, Peter McCroskery, Jinghui Dong, Marco Andreas Schupp, Hairong Xu, Krish Patel
Publikováno v:
Journal of Clinical Oncology. 40:7567-7567
7567 Background: Despite the success of axi-cel, ≈60% of patients (pts) have no response or relapse within ̃2 y after Tx (Jacobson C, et al. ASH 2021. #1764), highlighting the need for more therapeutic strategies. In preclinical studies, Rtx augme
Autor:
Kimberly Umans, Heinz Wiendl, Peter McCroskery, Wanda Castro-Borrero, Oksana Mokliatchouk, Giorgio Giannattasio, Steven J. Greenberg, Benjamin Turner, Gavin Giovannoni
Publikováno v:
Multiple Sclerosis Journal. 24:1725-1736
Background: Reversible lymphocyte count reductions have occurred following daclizumab beta treatment for relapsing–remitting multiple sclerosis. Objective: To analyse total and differential lymphocyte levels and relationship with infection status.
Autor:
Marianne T. Sweetser, Ludwig Kappos, Krzysztof Selmaj, Bhupendra Khatri, Kimberly Umans, Gavin Giovannoni, Steven J. Greenberg, Jacob Elkins, Peter McCroskery, Ralf Gold
Publikováno v:
Multiple Sclerosis and Related Disorders. 9:36-46
Background Daclizumab has been evaluated in multicentre, randomised, double-blind studies for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Safety and tolerability are key considerations in MS treatment selection, as t
Autor:
Xiaojun You, James G. Krueger, Firas Hougeir, Adam J. Friedman, Nisha Lucas, Marianne T. Sweetser, Jacob Elkins, Steven J. Greenberg, Wanda Castro-Borrero, Leon H Kircik, Peter McCroskery
Publikováno v:
Advances in Therapy
Introduction Cutaneous adverse events (AEs) have been observed in clinical studies of daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis (RRMS). Here, we report cutaneous AEs observed in the randomized, double-blind, active
Autor:
Allan Gibofsky, Michael Schiff, Peter McCroskery, Edward C. Keystone, Scott Baumgartner, William R Palmer, Jingyuan Feng, Joseph A. Markenson
Publikováno v:
The Journal of Rheumatology. 38:21-28
Objective.To report the rates of serious adverse events (SAE), serious infectious events (SIE), and events of medical interest (EMI) in patients receiving etanercept; to identify the risk factors for SAE, SIE, and EMI; and to report time to switching
Autor:
Joel M. Gelfand, Gregory Kricorian, Paul S. Yamauchi, Alan Menter, Yifei Shi, Craig F. Teller, Peter McCroskery, Alexa B. Kimball, Kara Creamer, David M. Pariser
Publikováno v:
Psoriasis Forum. :3-7
Background OBSERVE-5 is collecting safety data from real-world use of etanercept in the treatment of psoriasis per a post-marketing commitment of the U.S. Food and Drug Administration. Methods This phase IV prospective, multicenter, 5-year observatio
Autor:
Joan Holman, Surekha Akella, Dusan Stefoski, Peter McCroskery, Krzysztof Selmaj, Eva Havrdova, Ralf Gold, Belen Tornesi, Christopher Hurst
Publikováno v:
Neurology and Therapy
Introduction Multiple sclerosis (MS) is more common in women and can occur during childbearing years; thus, information on outcomes following exposure to MS therapy during pregnancy is important. No formal studies of daclizumab have been conducted in
Autor:
Nataliya Chernyukhin, Consuelo Blosch, Debra Zack, Daniel J. Lovell, Carol A. Wallace, Peter McCroskery, Scott Stryker
Publikováno v:
Pediatric Rheumatology Online Journal
Pediatric Rheumatology Online Journal, Vol 8, Iss 1, p 18 (2010)
Pediatric Rheumatology Online Journal, Vol 8, Iss 1, p 18 (2010)
Background Concerns have been raised about a potential link between the use of TNF inhibitors and development of malignancy in the pediatric population. We examined the worldwide experience of etanercept use in pediatric patients and the occurrence o